Illumina is following up its big news earlier this week that its new HiSeq X10 system can make the $1,000 genome possible by announcing a partnership with Amgen to develop and commercialize a multigene, next-generation sequencing-based test as a companion diagnostic for Amgen’s anticancer drug Vectibix (panitumumab). The firms plan to seek premarket approval of the test by the FDA and other regulatory agencies per the agreement.

Vectibix is a fully human anti-EGFR monoclonal antibody therapeutic designed to treat metastatic colorectal cancer. The aim of the collab, according to the companies, will be to validate a test platform that can identify the RAS mutation status of patients who would be good candidates for treatment with Vectibix. The test will be developed for use with Illumina’s MiSeqDx™ instrument, and Illumina plans to commercialize the test with a focus on U.S. and EU markets pending regulatory approval in both locations.

Nick Naclerio, svp, corporate and venture development and general manager of Illumina’s Enterprise Informatics, said in a statement that this agreement is part of the company’s strategy to bring NGS to the clinical diagnostics field.

“With three FDA-cleared NGS products in our portfolio, we intend to complement internal development programs by taking products developed with external partners through the FDA submission process. Amgen is a key partner given their leadership in therapeutic development and strong track record in commercializing novel products,” he added.

This site uses Akismet to reduce spam. Learn how your comment data is processed.